Lonny J. Carpenter Sells 5,000 Shares of Stryker Corporation (SYK) Stock
Stryker Corporation (NYSE:SYK) insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the sale, the insider now owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Stryker Corporation (SYK) traded up 0.10% during mid-day trading on Monday, reaching $146.67. 466,809 shares of the company’s stock traded hands. The stock’s 50 day moving average is $142.76 and its 200-day moving average is $134.44. The stock has a market capitalization of $54.86 billion, a PE ratio of 32.74 and a beta of 0.80. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $148.84.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm’s revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.39 earnings per share. On average, equities analysts anticipate that Stryker Corporation will post $6.50 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be paid a $0.425 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a yield of 1.16%. Stryker Corporation’s dividend payout ratio is currently 37.95%.
SYK has been the subject of several analyst reports. Deutsche Bank AG restated a “buy” rating and issued a $148.00 target price (up previously from $135.00) on shares of Stryker Corporation in a report on Saturday, April 29th. BidaskClub lowered shares of Stryker Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Zacks Investment Research upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price for the company in a report on Monday, July 17th. Stifel Nicolaus raised their target price on shares of Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Cowen and Company reiterated a “buy” rating and set a $160.00 price objective (up previously from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $144.03.
A number of institutional investors have recently made changes to their positions in SYK. Bollard Group LLC raised its position in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock worth $109,000 after buying an additional 3 shares during the period. Assetmark Inc. raised its position in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after buying an additional 4 shares during the period. Blue Chip Partners Inc. raised its position in shares of Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock worth $234,000 after buying an additional 6 shares during the period. Guardian Life Insurance Co. of America raised its position in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after buying an additional 9 shares during the period. Finally, FineMark National Bank & Trust raised its position in shares of Stryker Corporation by 0.4% in the second quarter. FineMark National Bank & Trust now owns 3,878 shares of the medical technology company’s stock worth $538,000 after buying an additional 15 shares during the period. Institutional investors own 73.99% of the company’s stock.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.